Roche launches onset Alzheimer's website

Share this article:
By Lauren Folino

To commemorate World Alzheimer's Day, Roche has launched the first available website dedicated to early-stage (prodromal) Alzheimer's disease, at EarlySymptomsAlzehimers.com.

The site, which caters to healthcare providers, patients and caregivers, was developed to draw attention to the latest progress in exploring the value of earlier diagnosis and treatment for Alzheimer's disease, according to Roche. Research has found that initial Alzheimer's symptoms can occur up to 12 years before diagnosis, which makes crucial the opportunity to recognize early-stage symptoms of the disease — such as significant memory loss and poor judgment and decision-making — so that therapeutic treatment may be administered before irreparable damage occurs.

While Roche has not yet brought to market any Alzheimer's treatments in the United States, the pharmaceutical manufacturer currently has a portfolio of four products in development for treating the disease. One treatment is in phase I and three are in phase II of clinical trials.

“In recent years, our understanding of the very early phases of Alzheimer's disease has improved significantly and more advanced diagnostic tools have become available to researchers in this field,” said Roche's global head of the neuroscience discovery and translational area, Luca Santarelli, M.D. “For this reason, we started clinical
trials that are looking at diagnosis and treatment of this disease much earlier, before significant damage to the brain has occurred.”

The website, which offers visitors a bevy of early Alzheimer's-related information, in addition to social tools such as videos and a blog, also provides patients with a downloadable “Tracker Diary” meant to act as a checklist that patients can fill out in order to recognize symptoms of the disease.

“We funded the EarlySymptomsAlzheimers site to help patients and medical professionals better understand this
new approach,” Dr. Santarelli added. “We hope that this will positively impact the diagnosis and treatment of Alzheimer's disease in the future.”
Share this article:

More in News

Bulk of Medicaid to be managed care in two years: Avalere

Bulk of Medicaid to be managed care in ...

More than three-quarters of Medicaid beneficiaries will be enrolled in a managed care plan as of 2016, according to an Avalere Health analysis released Thursday. The numbers reveal that managed ...

Nursing home asked for employee's personal information too often, jury rules

The human resources department of a Maine nursing home did not properly protect a former employee's personal identification information, a jury recently ruled.

Test could confirm sepsis within an hour

Nursing home residents might benefit from a new way of diagnosing and treating sepsis made possible by discoveries out of the University of British Columbia.